Abstract

Depletion of the central metabolite NAD in cells results in broad metabolic defects leading to cell death and is a proposed novel therapeutic strategy in oncology. There is, however, a limited understanding of the underlying mechanisms that connect disruption of this central metabolite with cell death. Here we utilize GNE-617, a small molecule inhibitor of NAMPT, a rate-limiting enzyme required for NAD generation, to probe the pathways leading to cell death following NAD depletion. In all cell lines examined, NAD was rapidly depleted (average t½ of 8.1 h) following NAMPT inhibition. Concurrent with NAD depletion, there was a decrease in both cell proliferation and motility, which we attribute to reduced activity of NAD-dependent deacetylases because cells fail to deacetylate α-tubulin-K40 and histone H3-K9. Following depletion of NAD by >95%, cells lose the ability to regenerate ATP. Cell lines with a slower rate of ATP depletion (average t½ of 45 h) activate caspase-3 and show evidence of apoptosis and autophagy, whereas cell lines with rapid depletion ATP (average t½ of 32 h) do not activate caspase-3 or show signs of apoptosis or autophagy. However, the predominant form of cell death in all lines is oncosis, which is driven by the loss of plasma membrane homeostasis once ATP levels are depleted by >20-fold. Thus, our work illustrates the sequence of events that occurs in cells following depletion of a key metabolite and reveals that cell death caused by a loss of NAD is primarily driven by the inability of cells to regenerate ATP.

Highlights

  • Depletion of NAD is a novel therapeutic strategy in oncology

  • When A549 and Calu-6 cells were incubated with ouabain or GNE-617, we found that both compounds induce similar cell blisters (Fig. 6A), suggesting that loss of plasma membrane ion homeostasis may be directly responsible for cell death following NAD depletion

  • Inhibition of nicotinamide phosphoribosyl transferase (NAMPT) leads to rapid depletion of cellular NAD levels, induces cell death, and is an attractive and novel therapeutic strategy in oncology

Read more

Summary

Background

Results: NAD depletion leads to loss of ATP and plasma membrane homeostasis. Depletion of the central metabolite NAD in cells results in broad metabolic defects leading to cell death and is a proposed novel therapeutic strategy in oncology. We utilize GNE-617, a small molecule inhibitor of NAMPT, a ratelimiting enzyme required for NAD generation, to probe the pathways leading to cell death following NAD depletion. Depletion of NAD with the small molecule inhibitor FK-866 or GNE-618 results in the attenuation of glycolysis [5, 7] This is attributed to reduced activity of the NAD utilizing enzyme glyceraldehyde-3-phosphate dehydrogenase, which converts glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate, decreasing carbon flow into the TCA cycle. Once ATP levels decrease by Ͼ20-fold, plasma membrane integrity is lost, leading to oncosis-mediated cell death

EXPERIMENTAL PROCEDURES
RESULTS
80 DMSO 60 200nM GNE-617
D ATP Depletion Timing
DISCUSSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call